Drugs / PF-08046033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07519655 | Apr 2026 → Jul 2028 expected | cutaneous melanoma, esophageal cancer, non-small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07519655 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT07519655 ↗ |